Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2–4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison

Puntos clave

• The aim is to compare the effectiveness of ciltacabtagene autoleucel and idecabtagene vicleucel in patients with relapsed or refractory multiple myeloma.
• Utilized matching-adjusted indirect comparison
• Analyzed outcomes for triple-class-exposed patients
• Considered patients with 2–4 prior lines of therapy
• Ciltacabtagene autoleucel showed improved overall response rates compared to idecabtagene vicleucel
• Data support the use of ciltacabtagene in treating heavily pre-treated myeloma
• Significant differences in progression-free survival between the two treatments observed